Pharmaceutical manufacturers are facing significant challenges in leveraging their data effectively, despite having access to vast amounts of information. Companies find themselves unable to make fully informed decisions about their patient access strategies due to incomplete visibility into the prescription journey.
The financial implications are substantial, with manufacturers experiencing significant gross-to-net reductions through necessary rebates for formulary placement. In 2023, brand-name drug
manufacturers saw GTN reductions reach $334 billion, marking a 10% increase from the previous year. The situation has become more challenging in 2024, with over 600 medications excluded from major formularies as pharmacy benefit managers strengthen their negotiating positions.
A major concern is the lack of visibility once prescriptions leave healthcare providers’ offices. Manufacturers lose track of
prescriptions that aren’t taken to pharmacies, aren’t enrolled in support programs, or are substituted before processing. Pharmacists often switch to generic alternatives when they believe a medication isn’t covered or when reimbursement for branded products is
insufficient, leaving manufacturers unaware of the actual number of written prescriptions or attempted fills.
These visibility gaps create tangible business impacts. Patient treatment initiation can be delayed or prevented when healthcare providers struggle with prior authorization submissions. Brand market share decreases when pharmacies make substitutions due to
reimbursement issues, despite successful marketing campaigns. Field teams waste valuable time when they can’t identify which territories have prior authorization submission problems.
Progressive manufacturers are now implementing comprehensive tracking systems across the entire prescription journey. Instead of focusing solely on operational metrics, they’re measuring success through patient outcomes and overall brand performance. Essential metrics include monitoring prior authorization completion rates, approval timelines, denial reasons, pharmacy dispensing patterns, and patient adherence trends.
To optimize prescription success, retail and specialty-lite teams must focus on several key areas: maximizing patient engagement to reduce prescription abandonment, ensuring appropriate out-of-pocket costs, addressing prior authorization obstacles, and managing reimbursement challenges. Providing field teams with territory performance data enables them to identify and support healthcare providers who may be struggling with utilization management requirements.
The ability to leverage comprehensive data is becoming a crucial differentiator in the pharmaceutical market. Companies that implement end-to-end visibility solutions gain advantages in both gross-to-net performance and strategic decision-making that benefits all
stakeholders. Real-time insights allow brand teams to quickly adjust their strategies to overcome access barriers, identify areas needing additional support, and optimize patient assistance programs.
As market access becomes increasingly complex, successful
pharmaceutical brands will need to transition from simply collecting data to generating actionable insights. This transformation is essential for ensuring patient access to medications while maintaining brand performance. Companies must adapt to growing formulary exclusions and evolving market dynamics by implementing robust data analysis capabilities.
The implementation of comprehensive metrics across the prescription journey is becoming essential. Key performance indicators should include new prescription volume, program enrollment rates, prior authorization approval rates, covered dispense percentages, pharmacy reimbursement rates, and patient refill patterns. These metrics provide crucial insights into program effectiveness and areas requiring improvement.
Field teams particularly benefit from access to detailed territory performance data, allowing them to identify specific providers who may need additional support or education. For instance, in territories where prior authorization submission rates average 80%,
representatives can focus their efforts on providers showing lower performance rates of 60-65%, providing targeted education and support to improve outcomes.
Be First to Comment